Cempra Inc. Daily Stock Analysis

Daily Stock Analysis, CEMP, Cempra Inc, priceseries

Cempra Inc. Daily Stock Analysis
Stock Information
Open
2.25
Close
2.33
High
2.35
Low
2.20
Previous Close
2.30
Daily Price Gain
0.03
YTD High
4.85
YTD High Date
Jul 5, 2017
YTD Low
2.05
YTD Low Date
Oct 27, 2017
YTD Price Change
-0.67
YTD Gain
-22.50%
52 Week High
8.20
52 Week High Date
Dec 5, 2016
52 Week Low
2.05
52 Week Low Date
Oct 27, 2017
52 Week Price Change
-3.58
52 Week Gain
-60.59%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Dec 5. 2014
14.42
Jan 15. 2015
25.17
27 Trading Days
74.57%
Link
LONG
Feb 13. 2015
27.68
Mar 23. 2015
37.71
25 Trading Days
36.25%
Link
LONG
Jul 14. 2015
38.25
Jul 30. 2015
42.49
12 Trading Days
11.10%
Link
LONG
Oct 27. 2015
20.09
Nov 12. 2015
27.31
12 Trading Days
35.95%
Link
LONG
May 20. 2016
15.76
Jun 10. 2016
18.31
14 Trading Days
16.20%
Link
LONG
Aug 1. 2016
18.50
Aug 19. 2016
22.96
14 Trading Days
24.12%
Link
LONG
Sep 12. 2016
22.65
Sep 29. 2016
23.93
13 Trading Days
5.66%
Link
LONG
Jun 19. 2017
3.95
Jul 6. 2017
4.48
12 Trading Days
13.45%
Link
Company Information
Stock Symbol
CEMP
Exchange
NasdaqGS
Company URL
http://www.cempra.com
Company Phone
919-576-2306
CEO
David Zaccardelli
Headquarters
North Carolina
Business Address
6320 QUADRANGLE DRIVE, SUITE 360, CHAPEL HILL, NC 27517-8149
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001461993
About

Cempra, Inc. engages as a clinical-stage pharmaceutical company, which focuses on the development of antibacterials to meet critical medical needs. Its products include; Solithromycin and Taksta. The company was founded by Prabhavathi B. Fernandes on November 18, 2005 and is headquartered in Chapel Hill, NC.

Description

Cempra, Inc., a clinical-stage pharmaceutical company, focuses on developing anti-infectives for the acute care and community settings to meet critical medical needs in the treatment of infectious diseases in North America. Its lead product candidate is solithromycin, which is in Phase III clinical trials developed in oral capsules, intravenous, and suspension formulations for the treatment of community-acquired bacterial pneumonia in adults and children, as well as for ophthalmic infections and other indications. The company is also developing fusidic acid, an antibiotic, which is in Phase III clinical trials for the treatment of acute bacterial skin and skin structure infections. In addition, it is developing other uses for solithromycin and fusidic acid, as well as analogs from its macrolide platform for non-infectious disease programs; and macrolides for treating diabetic gastroparesis and gastroesophageal reflux disease. It has a collaborative research and development and license agreement with Optimer Pharmaceuticals, Inc. The company was formerly known as Cempra Holdings, LLC and changed its name to Cempra, Inc. in February 2012. Cempra, Inc. was founded in 2005 and is headquartered in Chapel Hill, North Carolina.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading